Acquisition Announced
BioMarin acquisition of Amicus Therapeutics
US$4.8bn equity value
Announced 19 Dec 2025 · US$14.50 cash per share
Advisers
Amicus Therapeutics
Target
- Financial adviser
- Legal adviser
- Fairness opinion
- Target
- Amicus Therapeutics
- Acquirer
- BioMarin
- Target based in
- United States
- Buyer based in
- United States
- Sector
- Biotech
- Tags
- Biotech, Rare Disease, Pharma
In the league tables
Similar deals
- Neurocrine Biosciences acquisition of Soleno Therapeutics Apr 2026 · US$2.9bn · Biotech
- Vertex Pharmaceuticals acquisition of Crinetics Pharmaceuticals Jul 2026 · US$10bn · Biotech
- Chiesi Group acquisition of KalVista Pharmaceuticals Apr 2026 · US$1.9bn · Pharma
- Quince Therapeutics acquisition of Orphai Therapeutics May 2026 · Biotech
- Biogen acquisition of Apellis Pharmaceuticals Mar 2026 · US$5.6bn · Biotech
Sources
- 19 Dec 2025 BioMarin and Amicus — BioMarin acquisition of Amicus Therapeutics investors.biomarin.com
- 2 Feb 2026 Definitive merger proxy statement (DEFM14A), AMICUS THERAPEUTICS, INC. sec.gov
- 6 Aug 2026 BioMarin — BioMarin acquisition of Amicus Therapeutics sec.gov




